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Background: The bioactive peptide endothelin-1 is elevated during and after car-
diopulmonary bypass and exerts cardiovascular effects through its 2 receptor sub-
types, endothelin-1A and endothelin-1B. Increased endothelin-1A receptor stimu-
lation after cardiopulmonary bypass can cause increased pulmonary vascular
resistance and modulate myocardial contractility. However, whether and to what
degree selective endothelin-1A blockade influences these parameters in the postby-
pass setting is not completely understood.
Objectives: Our objective was to measure left ventricular function and hemody-
namics in a porcine model of cardiopulmonary bypass after selective blockade of
endothelin-1A.
Methods: Adult pigs (n = 23) underwent 90 minutes of cardiopulmonary bypass and
were randomized 30 minutes after bypass to receive a selective endothelin-1A
antagonist (TBC 11251, 10 mg/kg; n = 13) or saline vehicle (n = 10).
Results: After bypass and before randomization, pulmonary vascular resistance rose
nearly 4-fold, and left ventricular preload recruitable stroke work fell to one third
of baseline values (both P < .05). In the vehicle group pulmonary vascular resis-
tance continued to rise, and preload recruitable stroke work remained reduced.
However, after endothelin-1A blockade, the rise in pulmonary vascular resistance
was significantly blunted compared with that in the vehicle group. Moreover, the
reduction in pulmonary vascular resistance with endothelin-1A blockade was
achieved without a significant change in systemic perfusion pressures.
Conclusions: The present study demonstrated that increased activity of the endothe-
lin-1A receptor likely contributes to alterations in pulmonary vascular resistance in
the postbypass setting. Selective endothelin-1A blockade may provide a means to
selectively decrease pulmonary vascular resistance without significant effects on
systemic hemodynamics. 
Neurohormonal system activation is common after cardiopul-monary bypass (CPB).1 For example, systemic levels of thepotent bioactive peptide endothelin-1 (ET-1) increase 2-fold to3-fold during and after CPB.2,3 The effects of ET-1 are mediat-ed through 2 main receptor subtypes, endothelin-1A (ETA) andendothelin-1B (ETB).4 In vascular beds stimulation of ETA
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receptors results in contraction. In contrast, stimulation of
endothelial ETB receptors causes vasorelaxation by
release of the vasodilators nitric oxide, epoprostenol
(prostacyclin), or both.5 ET-1 has also been shown to
affect myocardial contractility.1,6,7 ET-1 is normally pres-
ent in the plasma at very low concentrations,8 but
increased systemic levels of ET-1 occur in a number of
disease states.8-12 The increased ET-1 level in the post-
CPB setting is associated with increased pulmonary arte-
rial pressure and vascular resistance.13-15 The nonselec-
tive ET-1 receptor antagonist, bosentan, has been
deployed in several cardiovascular disease states.16,17 For
example, in both clinical and experimental models of pul-
monary hypertension, nonselective ET-1 blockade with
bosentan decreased systemic and pulmonary vascular
resistance (PVR).17 The pulmonary vascular endothelium
has a significant role in local regulation and maintenance
of normal pulmonary vasomotor tone and in mediating the
hypertensive response to CPB.3,18,19 Endothelial ETB
receptor stimulation induces vasorelaxation, particularly
in the pulmonary bed.20 Furthermore, the ETB receptor is
an important clearance mechanism for circulating ETs.21
Thus blockade of the ETB receptor in the post-CPB set-
ting may not be desirable, and selective ETA receptor
inhibition may be of greater utility. Accordingly, the goal
of this study is to evaluate the effects of selective ETA
receptor antagonism after CPB on pulmonary and sys-
temic hemodynamics.
Methods
Overview
For these studies, an intact porcine model of CPB with cardio-
plegic arrest was used.22 After baseline measurements under nor-
mothermic conditions, CPB with myocardial arrest using conven-
tional hypothermic crystalloid cardioplegic solution was instituted.
After reperfusion and separation from CPB, hemodynamics were
assessed, and the pigs were randomized to either ETA receptor
inhibition or vehicle. Measurements were then performed for 90
minutes after separation from CPB. All animals were treated and
cared for in accordance with the National Institutes of Health
“Guide for the Care and Use of Laboratory Animals” (National
Research Council, Washington, 1996).
Drug and Dose Selection
For these studies, the selective ETA receptor antagonist TBC 11251
(Texas Biotechnology Corporation, Houston, Tex) was used. This
compound has demonstrated high specificity for the ETA receptor
and is one of the most selective ETA antagonists reported.23 In an
initial series of studies, chronically instrumented pigs were used to
perform arterial pressure response studies, as described in previous
studies.24 In brief, 5 pigs (20 kg, Hambone Farms) chronically
instrumented with an aortic access catheter received an intravenous
injection of ET-1 (0.4 µg/kg, Sigma Chemical Co, St Louis, Mo).
Blood pressure was recorded at baseline and continuously for 20
minutes after ET-1 administration. After hemodynamics had
returned to baseline values, TBC 11251 at 10 mg/kg was reconsti-
tuted to a standard volume of 5 mL by means of sterile saline solu-
tion and infused intravenously over a 10-minute period.
Hemodynamic measurements were repeated at 1 to 20 minutes after
injection. This dose of the ETA antagonist did not significantly
reduce resting arterial pressure. A second ET-1 challenge was
administered, and blood pressure and heart rate were recorded con-
tinuously for at least 30 minutes after the challenge. Satisfactory
ETA receptor blockade was defined as an approximately 75%
reduction in the ET-1–mediated increase in arterial pressure. The
dose used in these studies resulted in significant inhibition of this
ET-1–mediated blood pressure response, as shown in Figure 1.
Thus an intravenous dose of 10 mg/kg was used in the CPB studies.
This initial study used an exogenous delivery of purified ET-1 to
define a dosing paradigm for the CPB study and does not necessar-
ily reflect the actions or plasma levels of this peptide in vivo.
CPB: Instrumentation and Measurements
For the CPB studies, 23 pigs (45 kg) were instrumented to mea-
sure hemodynamics and left ventricular (LV) function.22 On the
day of the study, the pigs were fully anesthetized, and arterial
pressure monitoring was instituted. A multiluminal thermodilu-
tion catheter (7.5F, Baxter Healthcare Corp, Santa Ana, Calif) was
then positioned in the pulmonary artery. The arterial line and pul-
monary artery catheter were connected to externally calibrated
transducers (Statham P23ID, Carolina Medical Inc, King, NC). A
median sternotomy was performed, and the great vessels were iso-
lated. A precalibrated microtipped transducer (7.5F; Millar
Instruments Inc, Houston, Tex) was placed in the LV apex through
a small stab wound and secured with a purse-string suture. A flow
probe was placed over the anterior portion of the ascending aorta
and connected to a digital flowmeter (HT107; Transonic Systems,
Cardiopulmonary Support and Physiology Joffs et al
Figure 1. The percentage change in mean arterial pressure after
infusion of 10 µg of ET-1 in conscious pigs (n = 5). Infusion of the
selective ETA antagonist (10 mg/kg TBC 11251) caused a signifi-
cant reduction in the ET pressor response. *P < .05 versus control
values.
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Inc, Ithaca, NY) for continuous measurement of LV stroke vol-
ume and cardiac output. The electrocardiographs, pressure wave-
forms, and flow-probe signals were recorded with a multichannel
recorder (Hewlett-Packard, Palo Alto, Calif), as well as being dig-
itized on a computer for subsequent analysis at a sampling fre-
quency of 250 Hz (80386 processor; Zenith Data Systems, St
Joseph, Mo). After collection of baseline hemodynamics and LV
function, the pigs were anticoagulated with sodium heparin (300
U/kg) to achieve an extended activated clotting time of longer
than 400 seconds (ACTII; Medtronic HemoTec, Inc, Englewood,
Colo). Arterial cannulation was obtained, and then a 12-gauge
catheter (DLP Inc, Grand Rapids, Mich) was placed at the root of
the aorta for intermittent infusion of cardioplegic solution and use
as an LV vent. Venous cannulation (34F; CR Bard Inc, Santa Ana,
Calif) was then performed, and CPB was initiated. The CPB cir-
cuit contained a membrane oxygenator (Bentley Univox Spiral
Gold, Bentley Laboratories, Irvine, Calif) and was driven by a
modular roller pump system (Sarns 5000, 3M Healthcare, Ann
Arbor, Mich). The aorta was crossclamped, and an oxygenated,
hypothermic crystalloid cardioplegic solution (500 mL of Na+,
130 mmol/L Cl–, 109 mmol/L K+, 24 mmol/L Ca2+, 1.8 mmol/L,
and 30 mEq/L HCO3– at 4°C) was delivered through the aortic
root catheter. CPB was continued for 90 minutes with 500 mL of
cardioplegic solution administered at 30-minute intervals after the
initial cardioplegic dose. During CPB, neither systemic hypother-
mia nor topical cooling were used, and total flow was maintained
within 2.5 to 3.0 L/min to maintain the mean systemic arterial
pressure at a goal of 75 mm Hg. At completion of the cardioplegic
arrest period, the crossclamp was removed, and the myocardium
was reperfused. If ventricular fibrillation occurred during the ini-
tial reperfusion period, defibrillation was performed at 20 J with
internal paddles. No inotropic or vasoactive agents were used at
any time during the protocol, and protamine was not adminis-
tered. At 30 minutes after crossclamp removal, LV function and
systemic hemodynamics were recorded. After these measure-
ments, the randomization scheme and experimental protocol were
initiated.
Randomization
At the 30-minute postbypass period, the 23 pigs were randomly
assigned to receive either vehicle alone or the ETA receptor antag-
onist, as shown in Figure 2. The randomization scheme was based
on ear tag numbers, and the treatment assignment remained blind-
ed to the investigators throughout the study. The cardiothoracic
surgery veterinarian maintained the code list, prepared the com-
pounds, and performed the infusion. The randomization codes
were not broken until the completion of the study protocol. LV
function and systemic hemodynamics were then measured at 60
and 90 minutes after separation from CPB.
Plasma Collection and Analysis
Plasma samples were obtained during the study for measurement of
plasma ET-1 levels in the presence and absence of ETA blockade.
Baseline collection occurred immediately after placement of the arte-
rial monitoring line. Blood samples were collected during CPB at 30,
60-, and 90-minute time points. The next sample collection occurred
after aortic crossclamp release and a 30-minute stabilization period,
just before randomization. Final samples were collected after ran-
domization at 30 and 60 minutes after ETA blockade or saline infu-
sion. All blood samples were collected from arterial catheters placed
after induction of anesthesia. Samples were collected in heparinized
tubes and immediately centrifuged. Plasma was decanted and stored
at –70°C until the time of assay. ET-1 levels were measured with a
commercially available high-sensitivity radioimmunoassay kit (RIK-
6901; Penninsula Laboratories, Inc, San Carlos, Calif) by using a pre-
viously described method.25
Data Analysis
Changes in LV function and hemodynamics after CPB with cardio-
plegic arrest were initially compared with baseline values by means
Figure 2. Schematic of the experimental design. After baseline mea-
surements of LV function and hemodynamics, CPB with complete
myocardial arrest was performed for 90 minutes. Measurements of
LV function and hemodynamics were performed at 30 minutes after
release of the aortic crossclamp and separation from CPB. At this
time, randomization was performed in a blinded fashion in which
pigs received the ETA antagonist or vehicle. Measurements were
then repeated for 60 and 90 minutes after CPB.
Figure 3. PVR significantly increased after crossclamp removal
and separation from CPB. In the vehicle group PVR increased in a
time-dependent manner, with longer periods after separation from
CPB. In marked contrast, PVR fell from 30-minute post-CPB values
after infusion of the ETA receptor antagonist. Sample sizes for
each time point are shown in Table 1. *P < .05 versus baseline val-
ues; +P < .05 versus 30 minutes after CPB; #P < .05 versus vehicle.
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of analysis of variance (ANOVA). Likewise, changes in plasma ET-1
concentrations before, during, and after CPB were compared with
baseline values by using ANOVA. Specific comparisons between
pre- and post-CPB values were performed with a Bonferroni adjust-
ed t test. Comparisons between untreated and treated groups at the
time points after CPB were examined with an ANOVA for repeated
measures. All statistical analyses were performed with statistical soft-
ware programs (BMDP Statistical Software Inc, Los Angeles, Calif).
Results are presented as means ± SEM.
Results
All of the pigs entered into the protocol were successfully
weaned from CPB and randomized at 30 minutes after
bypass. Summary LV function and hemodynamic values are
presented in Table 1. LV function and mean arterial pressure
were reduced after cardioplegic arrest and CPB. Heart rate
and pulmonary artery pressure were increased at 30 minutes
after separation from CPB. In both the vehicle (n = 10) and
ETA blockade groups (n = 13), arterial pressure remained
reduced throughout the study period. Mean pulmonary
artery pressure was significantly lower in the ETA receptor
blockade group at 60 and 90 minutes after CPB. Systemic
vascular resistance was reduced in the ETA receptor block-
ade group when compared with that of the vehicle group but
did not reach statistical significance (P = .25).
The change in PVR after separation from CPB is sum-
marized in Figure 3. A significant increase in PVR occurred
at 30 minutes after CPB. In the vehicle group PVR
increased in a time-dependent manner after separation from
CPB. In marked contrast infusion of the ETA antagonist
completely inhibited this time-dependent increase in PVR
and allowed for a return toward baseline values.
The plasma ET-1 level at baseline was 6.0 ± 0.82 ng/mL,
approximating reported normal values.8 Changes in plasma
ET-1 levels are shown in Figure 4. Expressed as the per-
centage change from baseline, plasma ET-1 levels increased
significantly from baseline at 30 minutes after CPB and
continued to increase in the ETA blockade group, with sig-
nificant difference from levels in the vehicle group at 90
minutes after CPB.
Discussion
Neurohormonal system activation is a common sequelae of
CPB.1 Elevated circulating levels of the bioactive peptide
ET-1 have been identified after CPB and persist into the
early postoperative period. 2,3 ET-1 has been shown to exert
potent vasoconstrictive effects on the pulmonary vascular
bed and to modulate myocardial contractility.6,7,10,20 The
major findings of this study were 2-fold. First, circulating
levels of ET-1 are elevated after competitive ETA receptor
blockade administered after CPB. Second, the introduction
of selective ETA receptor blockade significantly blunted the
rise in PVR after CPB without significantly affecting sys-
temic perfusion pressures.
The effects of ET-1 are mediated through 2 predomi-
nant receptor subtypes, ETA and ETB.4,10 The ETA recep-
tor is expressed mainly on vascular smooth muscle cells,
where it activates a second messenger system, resulting in
increased intracellular Ca2+ concentrations and contrac-
tion.26 The ETA receptor also appears to modulate the
inotropic effect of ET-1.26,27 The ETB receptor is found
mainly on endothelial cells, where activated second mes-
senger systems induce the release of nitric oxide and
epoprostenol, with resultant vascular relaxation.4,5 The
ETB receptor is also a vital clearing mechanism for ET-
1.21 Given the elevated levels of ET-1 after CPB, blockade
of the potentially beneficial effects of the ETB receptor
may not be desirable. Consistent with past reports, this
study demonstrated elevated circulating levels of ET-1
after CPB.2,3 This study also demonstrated significantly
higher plasma ET-1 concentrations in the group receiving
ETA blockade. This is not unexpected because the drug
used in the study is a competitive inhibitor, and elevated
levels likely reflect displacement of ET-1 from ETA
receptors. This provides further evidence that the dose of
ETA antagonist used in the present study provides a phar-
macologic effect at the level of the ET receptor system.
The underlying mechanisms for increased vasoconstric-
tion within the pulmonary circuit in the early post-CPB set-
ting are likely multifactorial. Acute ETA receptor inhibition
significantly blunted the rise in PVR after CPB without sig-
nificantly affecting systemic perfusion pressures, thus pro-
viding direct evidence that ETA receptor activation within
the pulmonary circuit is a contributing factor. Right ventric-
ular dysfunction is not uncommon after CPB,28,29 and
Cardiopulmonary Support and Physiology Joffs et al
Figure 4. Plasma ET-1 levels, expressed as percentage change
from baseline, increased significantly after CPB. ET-1 levels con-
tinued to rise after infusion of the ETA receptor antagonist, with
significant difference from vehicle by 90 minutes after CPB. *P <
.05 versus baseline values; +P < .05 versus 30 minute after CPB; #P
< .05 versus vehicle.
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increased PVR can exacerbate this condition. Inhaled nitric
oxide has been demonstrated to reduce PVR in patients after
cardiac operations.30,31 ETB receptor stimulation provides
an intrinsic pathway of nitric oxide and epoprostenol pro-
duction, contributing to physiologic vasodilation in the pul-
monary circuit. In the present study the infusion of a selec-
tive, competitive ETA antagonist resulted in increased
circulating levels of ET-1. Increased plasma ET-1 in this set-
ting could lead to enhanced ETB receptor activation, with
subsequent pulmonary vasodilation. Thus, the reduction
seen in PVR with selective ETA receptor blockade may
occur through 2 complementary mechanisms: through the
direct antagonism of ETA receptor–mediated vasoconstric-
tion and through the potentiation of ETB receptor–mediated
vasorelaxation.
In addition to effects in the pulmonary vascular bed, ET-1
has been shown to influence contractile function in the
myocardium both in intact animal preparations and in isolated
myocyte systems.6,7,9 Exposure of normal myocardial prepa-
rations to increasing concentrations of ET-1 has been shown to
induce a mild positive inotropic effect.14 However, with under-
lying myocardial contractile dysfunction, increased ET-1 lev-
els exert a negative inotropic effect.6 The effects of ETA recep-
tor blockade on indices of global LV ejection performance
observed in the present study need to be considered in the con-
text of the experimental design used versus the clinical CPB
setting. Inotropic stimulation with calcium, β-adrenergic
receptor antagonists, or both is commonly performed in the
early post-CPB setting; however, in the present study no
vasoactive or inotropic interventions were used because these
would have confounding influences on the experimental
design. Thus, whether and to what degree ETA receptor block-
ade would influence myocardial contractile performance
remains to be established.
Although a number of studies have documented
increased ET-1 levels after CPB,2,3 the investigations with
ET-1 blockade are limited, with the majority using nonse-
lective ET-1 blockade or a converting enzyme inhibitor.32-34
Of the studies with selective ETA antagonism, the primary
focus has been animal models of congenital heart dis-
ease.35,36 For example, a recent study evaluated the effect of
selective ETA antagonism in a lamb model of experimental-
ly induced high flow pulmonary hypertension.35 The inves-
tigators were able to show that PVR was significantly lower
after CPB in lambs pretreated with the selective antagonist.
The present study builds on these reports by using a con-
ventional model of CPB and specifically evaluating sys-
temic perfusion indices and myocardial performance in
addition to pulmonary hemodynamics.
Many cardiac operations require CPB, with the potential
for some degree of postoperative hemodynamic instability.
Although off-pump coronary revascularization is an option for
selected patients, CPB is still necessary for a significant num-
ber of patients undergoing coronary bypass.37,38 In effect, the
most compromised coronary patients are frequently selected
out to undergo operation with CPB, and CPB is still necessary
for most valve and extensive aortic procedures. Thus,
improved strategies for preventing and treating the hemody-
namic sequelae of CPB are a significant clinical goal. The
present study demonstrated that selective ETA antagonism
blunted the inevitable rise in PVR in a porcine model of CPB
without affecting systemic hemodynamic stability. These
results suggest that selective ETA blockade may prove a use-
ful new therapeutic modality in the limited armamentarium for
treatment of pulmonary hypertension after CPB.
We thank Simona C. Baicu, Jeffrey A. Sample, Nancy Harper,
Mary C. King, Karla Zeigler, Joseph Sistino, and Dr Tom Brock
for their time and expertise.
TABLE 1. Hemodynamics and cardiac performance after CPB and cardioplegic arrest: Effects of selective ETA receptor
blockade
Time after CPB (min)
30 60 90
Baseline Vehicle ETAB Vehicle ETAB
Heart rate (beats/min) 86 ± 5 119 ± 6* 118 ± 6* 126 ± 6* 121 ± 5* 124 ± 6*
Cardiac output (L/min) 4.2 ± 0.2 3.5 ± 0.2* 3.5 ± 0.5 3.6 ± 0.3 3.2 ± 0.4* 3.9 ± 0.4
Stroke volume (mL/beat) 37.5 ± 2.1 18.8 ± 1.9* 23.4 ± 2.6* 16.2 ± 1.7*† 20.4 ± 2.8* 18.2 ± 2.5*
Stroke work (× 105 dyne · cm) 48 ± 3 15 ± 2* 19 ± 2* 12 ± 2*† 17 ± 2* 14 ± 3*
Mean arterial pressure (mm Hg) 97 ± 3 58 ± 3* 62 ± 4* 55 ± 6* 62 ± 3* 56 ± 6*
LV end-diastolic pressure (mm Hg) 8.3 ± 0.7 10.1 ± 0.9 9.2 ± 1.4 8.8 ± 1.2 9.1 ± 1.6 9.1 ± 1.3
Mean pulmonary arterial pressure (mm Hg) 11.4 ± 0.8 19.2 ± 1.0* 23.1 ± 1.0*‡ 16.7 ± 1.6*† 24.6 ± 1.2*‡ 15.8 ± 2.0*†‡
Systemic vascular resistance (dyne · s–1 · cm–5) 1830 ± 120 1029 ± 84* 1240 ± 195* 977 ± 173* 1328 ± 237.2* 1075 ± 216*
Sample size (n) 23 23 10 13 10 13
ETAB, Endothelin selective receptor blocker TBC 11251 (10 mg/kg).
*P < .05 versus before CPB.
†P < .05 versus vehicle.
‡P < .05 versus 30 minutes after crossclamp release.
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